A top 10 international pharmaceutical company leveraged H1 to identify HCPs seeing diverse patients with a given cardiovascular disease and within a 50-mile radius of the existing trial sites in the United States.
Ensuring access to clinical trials for women and minorities in cardiovascular disease is essential for promoting health equity, improving medical research, and developing effective treatments that benefit all segments of the population. It is a crucial step in addressing healthcare disparities and advancing the field of cardiovascular medicine.
A top 10 international pharmaceutical company struggling to recruit women and minorities in its Cardiovascular clinical trial tapped H1 to identify HCPs seeing diverse patients with a given cardiovascular disease and within a 50-mile radius of the existing trial sites.
The company specifically wanted to increase women and minority participation for clinical trial recruitment across trials. The ideal cohort needed to be 50% women participation to ensure coverage and clinical benefit beyond that of what competitor trials have enrolled across this indication. They tapped H1’s clinical trial platform to access key data insights to build and roll out target HCP lists to feasibility teams.
Download the case study.
Offered Free by: H1
See All Resources from: H1